

**Maria Elisa Perico**

Curriculum vitae

Birth: January, 31<sup>st</sup> 1974, Bergamo, Italy  
Home Address: via Nicola Pasetto 6/A, 37030 Lavagno (Verona), Italy  
Telephone: +39-328-7194035  
E-mail: [perico.mariaelisa@libero.it](mailto:perico.mariaelisa@libero.it)

**STUDY TITLES**

- April, 2014: PhD in Translational Biomedicine, University of Verona, Italy.
- March, 2002: national qualification examination (esame di stato) 175/180, University of Milan, Italy.
- December, 1998: Graduated in Biology 108/110, University of Milan, Italy.
- July, 1993: High School Diploma 60/60, "Liceo Scientifico, A.Banfi" Vimercate (MB), Italy.

**FORMATION AND WORK EXPERIENCES**

- from January 2014 at today: fellowship, Department of Neurological and Movement Sciences, University of Verona, Italy.
- January 2011 – December 2013: fellowship in Translational Biomedicine (XXVI cycle), Section of Immunology, Department of Pathology and Diagnostic, University of Verona, Italy.
- February 2006-June 2009: Scientist, Safety Assessment, GlaxoSmithKline, Verona, Italy.
- April 2005–January 2006: Associate Scientist, Safety Assessment, GlaxoSmithKline, Verona, Italy.
- July 2004-March 2005: fellowship MIUR-FIRB, Department of Pharmacology and Anaesthesiology, University of Padova, Italy.
- December 2003-May 2004: graduated technician, Inpharzam Ricerche SA – Zambon Group, Taverne (Switzerland).
- April 2002-October 2003: Assistant Research Scientist, Psychiatry CEDD-Biology, GlaxoSmithKline, Verona, Italy.
- October 2000–March 2002: fellowship PNR, Cancer Immune- Gene- Therapy Program, DIBIT-Ospedale San Raffaele, Milano, Italy.
- January 1999-September 2000: post-lauream training (March 1999-March 2000) and fellowship, Experimental Oncology Department, Istituto Nazionale Tumori, Milano, Italy.

- January 1997-December 1998: thesis preparation, Experimental Oncology E Division, Istituto Nazionale Tumori, Milano, Italy.

## **RESEARCH AREAS**

### Experimental Oncology:

- Cancer active immunotherapy, by synthetic or cellular mouse vaccination protocols.
- Biochemical characterization of membrane receptors associated to ovarian carcinoma; signal transduction characterization, mediated by specific receptor associated to prostatic carcinoma.

### Molecular Neurobiology:

- Molecular characterization of inducible transgenic mouse over-expressing CRF.
- Molecular characterization of *in vitro* SSRI-treated neural progenitors, derived from primary cultures of rat cerebellar granule cells.

### Molecular & Cellular Toxicology:

- Gene expression analysis to evaluate the hepatic toxicology, following *in vivo* rat treatment with potential drug compounds.
- Evaluation by flow cytometry of drug-induced phospholipidosis in preclinical species.

## **PUBLICATIONS**

1. E. Vicentini, R. Arban, O. Angelici, G. Maraia, M.E. Perico, M. Mugnaini, A. Ugolini, C. Large, E. Domenici, P. Gerrard, D. Bortner, I. Mansuy, L. Mangiarini and E. Merlo-Pich. "Transient forebrain over expression of CRF induces plasma corticosterone and mild behavioural changes in adult conditional CRF transgenic mice." *Pharmacology, Biochemistry and Behavior*, 2009; 93(1):17-24.
2. M.E. Perico, F. Crivellente, I. Faustinelli, A. Suozzi and P. Cristofori. ""Flow cytometry, with double staining with Nile red and anti-CD3 antibody, to detect phospholipidosis in peripheral blood lymphocytes of rats treated with Amiodarone." *Cell Biology & Toxicology*, 2009; 25(6): 587-598.
3. L. Lay, L. Panza, L. Poletti, L. Prosperi, S. Canevari and M.E. Perico. "Improvement of the synthesis of immunological carbohydrate vaccines containing the tumor associate antigen CaMBr1". *European Journal of Organic Chemistry*, Vol.2001, No. 22, 4331-4336 (2001).
4. M.E. Perico, M. Chinol, A. Nacca, E. Luison, G. Paganelli, S. Canevari. "The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier presentation." *The Journal of Nuclear Medicine*, Vol.42, No.11: 1697-1703, (2001).
5. M.E. Perico, D. Mezzanzanica, E. Luison, P. Alberti, L. Panza, G. Russo, S. Canevari. "Development of a new vaccine formulation that enhances the immunogenicity of

- tumor-associated antigen CaMBr1." *Cancer Immunology Immunotherapy* Vol. 49, No. 6: 296-304, (2000).
6. E. Adobati, A. Zucchetti, M.E. Perico, F. Cremonesi, G. Rasi, P. Sinibaldi Vallebona, M. Hagenaars, P.J.K. Kuppen, I. Pastan, L. Panza, G. Russo, M. I. Colnaghi, S. Canevari. "Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: Implication for the development of human-derived cancer vaccines." *The Histochemical Journal*. Vol. 31, No.11: 729-737, (1999).

## CONGRESS COMMUNICATIONS

1. *17<sup>th</sup> Joint Meeting: Signal Transduction. Receptors, Mediators and Genes. Weimar (Germany) 4-6 November 2013.* "The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells." S. Grasso, M.E. Perico, S. Schmidt, P. Shukla, V. Antonini, G. Fracasso, H. Naim, M. Colombatti, D. Ramarli.
2. International Meeting of the German Society for Cell Biology-Molecular Concepts in epithelial differentiation, pathogenesis and repair, Leipzig (Germany) 7-10 November 2012. "Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells." S. Grasso, M.E. Perico, S. Schmidt, P. Shukla, V. Antonini, G. Fracasso, H. Naim, M. Colombatti, D. Ramarli.
3. *ABCD Congress 2011, Ravenna (Italia), 8-10 settembre 2011.* "Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells." S. Grasso, P. Shukla, M.E. Perico, V. Antonini, G. Fracasso, D. Ramarli.
4. *27<sup>th</sup> Annual Symposium of Society of Toxicologic Pathology, San Francisco (USA), June 22-26, 2008.* "Analysis of peripheral leucocytes in rat model of amiodarone-induced phospholipidosis: comparison between electron microscopy (TEM), flow cytometry and light microscopy (LM)." F. Crivellente, I. Faustinelli, M.E. Perico, A. Suozzi, P. Cristofori.
5. *National Congress of the Italian Society of Neuroscience, Verona (Italia), 27-30 Settembre 2007.* "Transient forebrain overexpression of CRF peptide increases morning plasma corticosterone in adult conditional CRF transgenic mice." Vicentini E., Arban R., Angelici O., Maraia G., Perico M.E., Ugolini A., Mugnaini M., Large C., Domenici E., Gerrard P., Bortner D., Mansuy I., Mangiarini L., Merlo-Pich E.
6. *8th Annual European Congress on Veterinary Clinical Pathology, Cambridge (UK), 5-8 September 2006.* "Flow cytometry to detect phospholipidosis in peripheral blood lymphocytes of rats treated with amiodarone." M.E. Perico, F. Crivellente, P. Cristofori. (Awarded oral presentation).

7. *32^ Congresso Nazionale della Societa' italiana di Farmacologia, Napoli (Italia) 1-4 June 2005.* "SSRI-chronic treatment induces a neurogenic response in rat cerebellar granular cells." Zusso M., Guidolin D., Perico M., Giusti P., Debetto P.-
8. *Neuroplasticity, neurotrophic factors and mood disorders- International Symposium, Pisa (Italia) 8-9 April 2005.* "Identification in rat cerebellar granule cell cultures of neural precursors able to proliferate and differentiate in response to chronic treatment with SSRI". Zusso M., Debetto P., Guidolin D., Perico M., Giusti P.
9. *ISPNE XXXV Annual Meeting, Glasgow, Scotland (UK), 18-21 July 2004.* "Generation and characterization of inducible CRF over-expressing transgenic mice". Vicentini E., Perico M.E., Ronca R., Bortner D., Mansuy I., Merlo Pich E., Mangiarini L.
10. *40^ American Society for Cell Biology Annual Meeting, San Francisco (USA), 9-13 December 2000.* "Membrane microdomains in human ovarian tumor cells." S.Miotti, M.E.Perico, M.Bagnoli, A.Tomassetti, A.Filippini, A.Prinetti, S.Sonnino, S.Canevari.
11. *European Life Scientist Organization (ELSO) Congress, Geneva (Switzerland), 2-6 September 2000.* "Membrane microdomains in human ovarian tumor and normal cells." S.Miotti, M.E.Perico, M.Bagnoli, A.Filippini, A.Prinetti, S.Sonnino, S.Canevari.
12. *XXVIII Joint SI-SIIC Meeting, Ferrara (Italia) 7-10 June 2000.* "Immune response to macrocyclic chelating agent DOTA: safety for new radioimmunotherapy approaches". M.E.Perico, M.Chinol, A.Nacca, G.Paganelli, S.Canevari.
13. *12th annual Pezcoller Symposium: Signalling Cross-Talk in Cancer Cells, Trento (Italia) 1-3 June 2000.* "Folate receptor forms complexes with cytoplasmic signalling molecules in ovarian cancer cells." S.Miotti, M.Bagnoli, A.Tomassetti, M.E.Perico, S.Canevari.
14. *Conference on Cancer Vaccine, Istituto Superiore di Sanità, Roma (Italia) 15-16 November 1999.* "Rational design of a saccharidic vaccine for breast cancer therapy." S.Canevari, M.E.Perico, G.Russo, L.Panza.
15. *XXVII Convegno Nazionale della Società italiana di Immunologia, Udine (Italia) 16-18 June 1999.* "Immunogenicity of a synthetic tetrasaccharide epitope, mimicking the tumor-associated antigen CaMBR1." M.E.Perico, D.Mezzananza, E.Luison, P.Alberti, L.Panza, G.Russo, S.Canevari.

## **LANGUAGES**

Good proficiency of spoken or written English and French.

## **COMPUTER SKILLS**

Practice of graphics and writing programs (Windows, Macintosh), database and WEB consultation.